SCHEMBL2278960

SCHEMBL2278960

CO[C@H]1CN[C@@H](C(=O)Nc2ccc3c(c2)CCN(C)CC3)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
CTSC P53634 1/20 0.40
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
CLK2 P49760 1/20 0.39
CLK3 P49761 1/20 0.39
DYRK1A Q13627 1/20 0.39
POLB P06746 1/20 0.39
USP2 O75604 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
LMNA P02545 3/20 0.38
HSD17B10 Q99714 1/20 0.38
HPGD P15428 1/20 0.37
KCNA1 Q09470 1/20 0.37
KCNAB1 Q14722 1/20 0.37
CASP3 P42574 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3440741 0.97 CLK2 (0.43) NPC1RAB9ACTSCHCRTR1HCRTR2
SCHEMBL12101328 0.96 ROCK2 (0.41) NPC1RAB9ACTSCHCRTR1HCRTR2
SCHEMBL4681769 0.83 CLK2 (0.38) NPC1RAB9AHCRTR1HCRTR2CLK2
SCHEMBL12101309 0.81 CTSC (0.38) NPC1RAB9ACTSCKDM4EALDH1A1
SCHEMBL3943257 0.80 CLK2 (0.42) NPC1RAB9ACLK2CLK3DYRK1A
SCHEMBL8476406 0.77 PSMB8 (0.56) NPC1RAB9AUSP2RXFP1KMT2A
SCHEMBL8132355 0.77 PSMB8 (0.46) NPC1RAB9AHCRTR1HCRTR2CLK2
SCHEMBL8225469 0.75 CTSC (0.36) CTSC
SCHEMBL3856353 0.75 ALDH1A1 (0.51) NPC1RAB9ACTSCPOLBKMT2A
SCHEMBL3856350 0.75 ALDH1A1 (0.51) NPC1RAB9ACTSCPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003639-B2 Substituted prolinamides, the preparation thereof and the use thereof as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-23 US disclosed
US-20090048231-A1 SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048231-A1 SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS PREP, P4HA1, PPID NPC1 3086/4885RAB9A 1664/4885CTSC 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.